SCHEMBL3018839

SCHEMBL3018839

COc1ccc(-c2csc(N3CCN(S(=O)(=O)c4cc(C(F)(F)F)ccc4Cl)CC3)n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.54
MAPT P10636 5/20 0.52
HSD17B10 Q99714 2/20 0.52
USP2 O75604 2/20 0.52
RECQL P46063 1/20 0.52
RAB9A P51151 3/20 0.51
NPC1 O15118 1/20 0.51
ALDH1A1 P00352 5/20 0.50
SMN1; SMN2 Q16637 5/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
LMNA P02545 4/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
MAPK1 P28482 4/20 0.48
TSHR P16473 1/20 0.48
ATM Q13315 1/20 0.48
TP53 P04637 1/20 0.45
ALOX15 P16050 1/20 0.45
HTT P42858 1/20 0.45
FAAH O00519 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016837 0.93 MAPT (0.54) POLBMAPTHSD17B10USP2RECQL
SCHEMBL3003370 0.91 MAPT (0.66) POLBMAPTHSD17B10USP2RECQL
SCHEMBL3017529 0.91 SMN1; SMN2 (0.48) POLBMAPTHSD17B10USP2RECQL
SCHEMBL3007795 0.90 SMN1; SMN2 (0.53) POLBMAPTHSD17B10USP2RECQL
SCHEMBL3013011 0.90 SMN1; SMN2 (0.54) MAPTHSD17B10RAB9ANPC1ALDH1A1
SCHEMBL3017333 0.90 SMN1; SMN2 (0.53) POLBMAPTHSD17B10USP2RECQL
SCHEMBL3011172 0.89 SMN1; SMN2 (0.52) POLBMAPTHSD17B10USP2RECQL
SCHEMBL3014003 0.88 REV1 (0.49) POLBMAPTHSD17B10USP2RECQL
SCHEMBL3013986 0.88 HSD17B10 (0.47) POLBMAPTHSD17B10USP2RECQL
SCHEMBL3006723 0.88 LMNA (0.57) MAPTHSD17B10USP2RECQLRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA POLB 4649/4885MAPT 18/4885HSD17B10 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.